Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions - Limited inhibition of the P2Y12 receptor

Concomitant aspirin and clopidogrel treatment failed to suppress platelet activity in 20% of patients. Non-responders to clopidogrel had decreased responses also to another ADP receptor antagonist, which suggests that the impaired response occurs at the level of P2Y12-receptor.